A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions

Sarcoma

Interventions

DRUG

ABSK043 single agent

ABSK043 BID continuously for 28 day cycle

Trial Locations (1)

RECRUITING

UHN- Princess Margaret Cancer Center, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT07014137 - A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas | Biotech Hunter | Biotech Hunter